These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26148022)

  • 1. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.
    Binder M; Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Lust JA; Kapoor P; Lin Y; Go RS; Hwa YL; Kyle RA; Kumar SK
    Am J Hematol; 2015 Oct; 90(10):888-91. PubMed ID: 26148022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
    Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.
    Tandon N; Sidana S; Rajkumar SV; Gertz MA; Buadi FK; Lacy MQ; Kapoor P; Gonsalves WI; Dispenzieri A; Kourelis TV; Warsame R; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Hwa YL; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Kumar SK
    Blood Adv; 2019 Mar; 3(5):744-750. PubMed ID: 30824418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.
    Suehara Y; Takamatsu H; Fukumoto K; Fujisawa M; Narita K; Usui Y; Takeuchi M; Endean K; Matsue K
    Cancer Sci; 2017 Feb; 108(2):187-192. PubMed ID: 27889936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma.
    Tan D; Lao Z; Loh Y; Ng HJ; Chuah C; Wong GC; Koh M; Linn YC; Lim LC; Tien SL; Lee LH; Goh YT; Hwang W
    Bone Marrow Transplant; 2010 Nov; 45(11):1625-30. PubMed ID: 20154737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
    Cerrato C; Di Raimondo F; De Paoli L; Spada S; Patriarca F; Crippa C; Mina R; Guglielmelli T; Ben-Yehuda D; Oddolo D; Nozzoli C; Angelucci E; Cascavilla N; Rizzi R; Rocco S; Baldini L; Ponticelli E; Marcatti M; Cangialosi C; Caravita T; Benevolo G; Ria R; Nagler A; Musto P; Tacchetti P; Corradini P; Offidani M; Palumbo A; Petrucci MT; Boccadoro M; Gay F
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1357-1366. PubMed ID: 29675792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
    Song MK; Chung JS; Joo YD; Lee SM; Lee GW; Lee HS; Kim SH; Yun EY; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
    Acta Haematol; 2010; 124(1):34-9. PubMed ID: 20606414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of 1027 patients with newly diagnosed multiple myeloma.
    Kyle RA; Gertz MA; Witzig TE; Lust JA; Lacy MQ; Dispenzieri A; Fonseca R; Rajkumar SV; Offord JR; Larson DR; Plevak ME; Therneau TM; Greipp PR
    Mayo Clin Proc; 2003 Jan; 78(1):21-33. PubMed ID: 12528874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.